Abstract:Background Tumors are characterized by extracellular matrix (ECM) remodeling and stiffening. The ECM has been recognized as an important determinant of breast cancer progression and prognosis. Recent studies have revealed a strong link between ECM remodeling and immune cell infiltration in a variety of tumor types. However, the landscape and specific regulatory mechanisms between ECM and immune microenvironment in breast cancer have not been fully understood. Methods Using genomic data and clinical information of breast cancer patients obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we conducted an extensive multi-omics analysis to explore the heterogeneity and prognostic significance of the ECM microenvironment. Masson and Sirius red staining were applied to quantify the contents of collagen in the ECM microenvironment. Tissue immunofluorescence (IF) staining was applied to identify T helper (Th) cells. Results We classified breast cancer patients into two ECM-clusters and three gene-clusters by consensus clustering. Significant heterogeneity in prognosis and immune cell infiltration have been found in these distinct clusters. Specifically, in the ECM-cluster with better prognosis, the expression levels of Th2 and regulatory T (Treg) cells were reduced, while the Th1, Th17 and T follicular helper (Tfh) cells-associated activities were significantly enhanced. The correlations between ECM characteristics and Th cells infiltration were then validated by clinical tissue samples from our hospital. The ECM-associated prognostic model was then constructed by 10 core prognostic genes and stratified breast cancer patients into two risk groups. Kaplan-Meier analysis showed that the overall survival (OS) of breast cancer patients in the high-risk group was significantly worse than that of the low-risk group. The risk scores for breast cancer patients obtained from our prognostic model were further confirmed to be associated with immune cell infiltration, tumor mutation burden (TMB) and stem cell indexes. Finally, the half-maximal inhibitory concentration (IC50) values of antitumor agents for patients in different risk groups were calculated to provide references for therapy targeting distinct ECM characteristics. Conclusion Our findings identify a novel strategy for breast cancer subtyping based on the ECM characterization and reveal the regulatory roles of Th cells in ECM remodeling. Targeting ECM remodeling and Th cells hold potential to be a therapeutic alternative for breast cancer in the future.

Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?

Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Extracellular matrix remodeling in the tumor immunity

Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment

Extracellular matrix and its therapeutic potential for cancer treatment

Biomaterials to regulate tumor extracellular matrix in immunotherapy

Targeting Extracellular Matrix Interaction in Gastrointestinal Cancer: Immune Modulation, Metabolic Reprogramming, and Therapeutic Strategies

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

The extracellular matrix in solid tumor immunotherapy

Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

Abstract 4275: Targeting tumor extracellular matrix to improve response to therapy

Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy

Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy

Role of tumor microenvironment in cancer progression and therapeutic strategy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?

The regulatory roles of T helper cells in distinct extracellular matrix characterization in breast cancer

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy

Advances in targeting tumor microenvironment for immunotherapy

The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis